LCHN_E330009J07Rik Inhibitors
Chemical inhibitors of LCHN_E330009J07Rik utilize various strategies to impede the protein's function by targeting different molecular pathways. Wortmannin and LY294002, both being phosphatidylinositol 3-kinase (PI3K) inhibitors, can directly disrupt the PI3K/AKT signaling pathway, which is pivotal for cellular processes such as metabolism and survival. By inhibiting PI3K, these compounds prevent the subsequent activation of AKT, consequently interfering with the function of proteins like LCHN_E330009J07Rik that are regulated by this pathway. Moreover, Spautin-1 contributes to this interference by promoting the degradation of PI3K, further diminishing AKT signaling. Rapamycin, an mTOR inhibitor, acts on a different node of the same pathway by inhibiting the mechanistic target of rapamycin (mTOR) and consequently affecting proteins downstream of mTOR, among which LCHN_E330009J07Rik may be included.
Additional compounds such as Palbociclib, PD98059, U0126, and SB203580 interfere with cellular signaling by targeting other crucial kinases and enzymes. Palbociclib's inhibition of cyclin-dependent kinases CDK4 and CDK6 halts cell cycle progression, which can impede the function of proteins like LCHN_E330009J07Rik that are involved in cell cycle-dependent processes. PD98059 and U0126, both MEK inhibitors, obstruct the MAPK/ERK pathway, thereby preventing the activation of proteins downstream in this pathway. SB203580 specifically targets p38 MAPK, inhibiting the p38 MAPK pathway and affecting associated cellular responses, which could include the activity of LCHN_E330009J07Rik. Src family kinases, another critical group in cellular signaling, are the target of PP2, which by inhibiting these kinases, can influence proteins functioning downstream of Src signaling, potentially including LCHN_E330009J07Rik. Dasatinib, a tyrosine kinase inhibitor, broadly inhibits BCR-ABL and Src family kinases, impacting multiple signaling pathways related to cell adhesion and structure, which could influence the function of LCHN_E330009J07Rik. Through these diverse mechanisms, these chemical inhibitors collectively contribute to the regulation of LCHN_E330009J07Rik's function within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent phosphatidylinositol 3-kinase (PI3K) inhibitor. By inhibiting PI3K, it can block the PI3K/AKT signaling pathway which is necessary for many cellular processes including metabolism and survival. As LCHN_E330009J07Rik is involved in cellular pathways that may be downstream of PI3K, Wortmannin can inhibit its function by hindering the pathway's activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another inhibitor of phosphatidylinositol 3-kinases. It prevents the phosphorylation and activation of PI3K, thereby inhibiting the PI3K/AKT pathway. Since LCHN_E330009J07Rik operates within cellular processes governed by this pathway, LY294002's action would result in functional inhibition of LCHN_E330009J07Rik by obstructing the signaling required for its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can broadly inhibit the mechanistic target of rapamycin (mTOR) pathway. This pathway is integral to cellular growth and proliferation. By inhibiting mTOR, Rapamycin can lead to the inhibition of downstream proteins that rely on mTOR signaling for their function, including LCHN_E330009J07Rik. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $168.00 | ||
Spautin-1 is known to promote the degradation of PI3K, which subsequently reduces AKT signaling. Inhibition of the AKT pathway would prevent activation of downstream proteins that depend on this pathway, potentially including LCHN_E330009J07Rik, thus inhibiting its function. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. These kinases are crucial for cell cycle progression. By inhibiting these kinases, Palbociclib can prevent the progression of the cell cycle, which could inhibit the function of LCHN_E330009J07Rik if it's involved in cell cycle-dependent processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor, which blocks the MAPK/ERK pathway. This inhibition can reduce the activity of downstream proteins that are regulated via the MAPK/ERK pathway, thereby functionally inhibiting proteins like LCHN_E330009J07Rik that may be implicated in this signaling cascade. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. It inhibits the p38 MAPK pathway, which is involved in stress responses and inflammation. Functional inhibition of LCHN_E330009J07Rik can occur if this protein operates as part of the cellular response modulated by p38 MAPK. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream of ERK in the MAPK/ERK pathway. If LCHN_E330009J07Rik is a downstream effector in this pathway, its function would be inhibited by U0126 due to the blockade of MEK1/2 activity and subsequent reduced ERK signaling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a Src family kinase inhibitor. Src kinases are involved in various signaling pathways that regulate cell growth and differentiation. Inhibition of Src kinases by PP2 can lead to the functional inhibition of proteins like LCHN_E330009J07Rik that may act downstream of Src signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor with activity against BCR-ABL and Src family kinases. It can inhibit multiple signaling pathways, including those that control cell adhesion and structure. If LCHN_E330009J07Rik functions within these pathways, Dasatinib would result in its inhibition. | ||||||